Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

5.060 +0.050 (+1.00%)
Streaming Delayed Price Updated: 10:06 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aurinia Pharm Ord

< Previous 1 2 3 4 5 Next >
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals finalizes acquisition agreement with Leading Pharma Giant
Via Get News
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Results of the 2021 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.